Keeps BioPharma (256940.KQ) Stock Price
Keeps BioPharma Price
Revenue has compounded at 34.9% per year over the past 10 years to 170.15 B KRW. Earnings per share have declined at 18.0% per year over the last 8 years. Keeps BioPharma's net margin stands at -5.8%, up from -359.5% several years earlier. Keeps BioPharma currently offers a dividend yield of about 0.60%. The payout ratio is around 6% of earnings. Analysts set a median price target of 16,830.00 KRW, implying 201.1% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Keeps BioPharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Keeps BioPharma business model & stock analysis
Frequently asked questions about Keeps BioPharma
Analysts currently set an average price target of 16,830.00 KRW for the Keeps BioPharma stock (median: 16,830.00 KRW), implying +201.1 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Keeps BioPharma stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Keeps BioPharma share trades at 3.75 EUR (5,590.00 KRW).
The revenue cannot currently be calculated for Keeps BioPharma.
The profit cannot currently be calculated for Keeps BioPharma.
The P/E ratio cannot be calculated for Keeps BioPharma at the moment.
The P/S cannot be calculated for Keeps BioPharma currently.
The Eulerpool Quality Score for Keeps BioPharma is 4/10.
The ISIN of Keeps BioPharma is KR7256940008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Keeps BioPharma is 256940.KQ. The ticker symbol is used to trade Keeps BioPharma shares on the stock exchange.
Keeps BioPharma stock
Keeps BioPharma Peer Group
Keeps BioPharma FIGI
All fundamentals and in-depth analysis of Keeps BioPharma
Our stock analysis for Keeps BioPharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Keeps BioPharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.